Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Adaptimmune Therapeutics

These two novel-drug makers could be top takeover targets next year.

2 Top Healthcare Stocks That Could Be Bought Out in 2022

CRISPR Therapeutics was down at one point 10% after hours following reports of poorer than expected efficacy levels for its CTX110 CAR-T cell therapy. CRISPR is currently (55%) off all-time highs set at the beginning of 2021.

Crispr Therapeutics: The Future Of Gene Therapy

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Wednesday.

Cathie Wood's ARK Invest Buys Over 675,000 More Shares of CRISPR

Shares of CRISPR Therapeutics AG (NASDAQ: CRSP) fell just under 10% on Wednesday as the biotech firm presented updated data for the phase 1 trial of its blood cancer candidate CTX 110.  RBC Capital maintained a ‘sector perform' rating In a new research report on Wednesday, RBC Capital Markets maintained a “sector perform” rating on […] The post CRISPR price outlook: RBC sees upside to $117 appeared first on Invezz.

CRISPR price outlook: RBC sees upside to $117

Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. The post CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today appeared first on InvestorPlace.

CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today

Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.

Why CRISPR Therapeutics Stock Is Sinking Today

CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-cell malignancies. “We are excited to share positive data from our CARBON trial, which show that CTX110 could offer patients with large B-cell lymphomas an immediately available ‘off-the-shelf' therapy with efficacy similar to autologous CAR-T and a differentiated safety profile,” said Samarth Kulkarni, CEO of CRISPR Therapeutics.

Why CRISPR Therapeutics Stock Is Tumbling Today

The stock price of CRISPR Therapeutics, a biotechnology gene editing company focused on developing gene-based medicines for human diseases, reached an all-time high of $210 in January of this year before a sell-off drove the stock price down over 50% to its current level of around $100.

Will CRISPR Stock Rebound After A 17% Fall In A Month?

The ARK Innovation ETF and ARK Genomic Revolution ETF cumulatively snapped up hundreds of thousands of shares in Crispr in the past week.

Cathie Wood's Ark Funds Built Up Big Stakes in Crispr. The Stock Is Now Tumbling.

Shares of Crispr Therapeutics Inc. CRSP, +1.93% were down 5.8% in premarket trading on Wednesday, the day after the company announced data from a Phase 1 clinical trial for its CAR-T cell therapy candidate. Wall Street analysts are skeptical about the experimental therapy's potential in the competitive CAR-T market.

Crispr's stock is down 5% after sharing early-stage data for its CAR-T therapy candidate

The stock price of Crispr Therapeutics AG (NASDAQ: CRSP) fell by over 6% today. This is why it happened.

CRSP Stock: Why It Fell Today

Vericel

Catalyst Pharmaceuticals

Hint: it doesn't really matter what kind of market it is.

How to Invest in Biotech Stocks in a Bear Market

-58% overall response rate (ORR) and 38% complete response (CR) rate in large B-cell lymphoma (LBCL) with a single dose of CTX110 at Dose Level 2 (DL2) and above on an intent-to-treat (ITT) basis-

CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies

A couple of ARK Invest funds run by ETF star Cathie Wood made a huge buy on Friday.

Cathie Wood's ARK Invest Buys Over 400,000 Shares of CRISPR

Shares of leading gene editing company CRISPR Therapeutics (CRSP) are sliding on Friday. What's behind the slump?

Why CRISPR Therapeutics (CRSP) Stock is Falling Today

CRISPR Therapeutics stock is now down roughly 33% across 2021's trading.

Why CRISPR Therapeutics Stock Fell 10.4% Last Month

-Management to host conference call and webcast on October 12th at 4:30 p.m. ET-

CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data

CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni Presents at Chardan's 5th Annual Genetic Medicines Conference Call Transcript

BioCryst Pharmaceuticals

Vertex Pharmaceuticals

A stock market that soured on biotech stocks in general is presenting some bargain opportunities.

3 Biotech Stocks Wall Street Thinks Could Rise 44% or Better

Nikola

Ocugen, Inc.

Vaxart

These companies could deliver jaw-dropping revenue growth through mid-decade.

4 Stocks Expected to Increase Sales 25,750% to 2,970,000% in 5 Years

Editas Medicine

Editas Medicine Inc (NASDAQ: EDIT) has announced initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101 for blindness due to Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.  Related Link:   Editas Medicine Unveils Preclinical Data From New Gene Editing Technology.

Here's Why Editas Stock Dropped After Data From CRISPR-Based Retinal Disorder Candidate

Bristol-Myers

Fulgent Genetics

If the market crashes these companies could be insulated.

These 3 Top Healthcare Stocks Are Screaming Buys Right Now

DraftKings

Roku

Shopify

Virgin Galactic

Block

Tesla

These top seven stocks among Cathie Wood's top holdings are ones investors may be enticed to consider right now. The post 7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio appeared first on InvestorPlace.

7 Cathie Wood Stocks Every Growth Investor Needs In Their Portfolio

ZUG, Switzerland and CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Chardan's 5th Annual Genetic Medicines Conference on Monday, October 4, 2021 at 2:00 p.m. ET.

CRISPR Therapeutics to Participate in the Chardan's 5th Annual Genetic Medicines Conference

Beam Therapeutics

Wood is following an important strategy with gene-editing stocks.

News for CRISPR Therapeutics Stock (CRSP)